Ask about this productRelated genes to: KIF5B antibody
- Gene:
- KIF5B NIH gene
- Name:
- kinesin family member 5B
- Previous symbol:
- KNS1
- Synonyms:
- KNS
- Chromosome:
- 10p11.22
- Locus Type:
- gene with protein product
- Date approved:
- 1998-08-24
- Date modifiied:
- 2015-08-28
Related products to: KIF5B antibody
Related articles to: KIF5B antibody
- Pulmonary mixed neuroendocrine and non-neuroendocrine neoplasms (MiNENs) are currently described in the World Health Organization (WHO) classification primarily as combinations of non-small cell lung cancer (NSCLC) and high-grade neuroendocrine carcinomas, such as small cell lung cancer (SCLC) or large cell neuroendocrine carcinoma (LCNEC). The coexistence of NSCLC with typical or atypical carcinoid (TC/AC) tumors is not officially recognized in the current classification and remains an exceptionally rare entity, with limited information on its pathogenesis. We sought to delineate the molecular alterations underlying a rare case of MiNEN composed of AC and adenocarcinoma. - Source: PubMed
Publication date: 2026/03/19
Kim Kyoung MinKim Jong HunChung Myoung Ja - Gliomas are the most frequent Central Nervous System (CNS) tumors in children and adolescents. Angiocentric glioma is a rare subtype of pediatric-type diffuse low-- grade gliomas with a relatively favorable prognosis following gross total resection. More recently, the identification of Anaplastic Lymphoma Kinase (ALK) fusions in glioma has led to the development of targeted therapeutics to improve responses and outcomes. - Source: PubMed
Publication date: 2026/05/08
Liu TaoShen GeZhou XiaoyanZhang GairongZou Lei - RET is a transmembrane receptor protein-tyrosine kinase that is required for the (i) survival and maturation of the enteric nervous system, the autonomic nervous system, and sensory neurons, (ii) renal development, and (iii) spermatogenesis. RET activation by its glial-cell derived neurotrophic factor (GDNF) ligands differs from that of all other receptor protein-tyrosine kinases because of the requirement for additional GDNF family receptor-α co-receptors (GFRα1/2/3/4, GFRAL). Activating RET-point mutations occur in multiple endocrine neoplasia syndromes (MEN2A, MEN2B) and in isolated medullary thyroid cancer. RET-fusion proteins, commonly KIF5B-RET, occur in NSCLC. More than three dozen fusion partners of RET have been described in papillary thyroid cancer. Several multikinase blockers targeting RET have been approved by the FDA for the treatment of cancer: (i) vandetanib for medullary thyroid carcinoma and (ii) cabozantinib, lenvatinib, and sorafenib for differentiated thyroid cancer. Pralsetinib is a specific RET blocker that is FDA-approved for the treatment of medullary thyroid cancer, RET-fusion positive thyroid cancer and NSCLC. Selpercatinib is FDA-approved for the management of RET-mutant medullary thyroid cancer, RET-fusion-positive thyroid cancer, and other RET-fusion-positive solid tumors. The RET signaling pathway participates in the pathogenesis of cancer, particularly in thyroid and lung cancer. Currently, the number of new cases of thyroid cancer bearing RET mutations or RET-fusion proteins is about 13,000 per year and the number of cases of RET-driven NSCLC range from about 2000-4000 per year in the United States. Inactivating RET mutations result in Hirschsprung disease, a congenital disorder leading to aganglionosis of the gastrointestinal tract. - Source: PubMed
Publication date: 2026/05/08
Roskoski Robert - fusion is a pathogenic driver factor in lung cancer patients. Currently, the conclusions on the clinical factors of fusion in NSCLC are inconsistent. - Source: PubMed
Publication date: 2026/04/28
Li XiangZhao PeiyanCui HeranZhang TingtingSun WenyuLi Hui - Resistance to third-generation EGFR tyrosine kinase inhibitors (TKIs) such as osimertinib remains a major challenge in the treatment of EGFR-mutated non-small cell lung cancer (NSCLC). While on-target and bypass mechanisms such as MET amplification are well-characterized, oncogenic fusions-particularly RET fusions-are emerging as relevant resistance mechanisms in a subset of patients. The feasibility of dual inhibition strategies and personalized monitoring through liquid biopsy remains underexplored in real-world clinical practice. - Source: PubMed
Publication date: 2026/03/18
Kropf-Sanchen CorneliaFrost NikolajKuon JonasWermke MartinKrüger StefanFuchs FlorianWiesweg MarcelChristopoulos PetrosThomas MichaelGaisa Nadine TJosten MichaelWenzel CarinaButh JanGlanemann FlorianStenzinger AlbrechtFroelich Matthias FJanning MelanieColienne MaikeHaselmann VerenaLoges Sonja